WO1997019063A1 - Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents
Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant Download PDFInfo
- Publication number
- WO1997019063A1 WO1997019063A1 PCT/FR1996/001847 FR9601847W WO9719063A1 WO 1997019063 A1 WO1997019063 A1 WO 1997019063A1 FR 9601847 W FR9601847 W FR 9601847W WO 9719063 A1 WO9719063 A1 WO 9719063A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- alkoxy
- alkyl
- ppm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- - Rj represents a fluorine, a hydroxy, a (C ⁇ ⁇ C5) alkoxy, a (C ⁇ -C5) alkylthio, a hydroxy (C ⁇ -C5) alkoxy, a group -N ⁇ lO ⁇ ll ' a cyano, a (Cj- C5) alkylksulfonyl, a (C ⁇ -C5) alkylsulfinyl;
- R2 and R3 represent a (C ⁇ -C4) alkyl or together with the nitrogen atom to which they are linked constitute a heterocyclic radical, saturated or unsaturated, of 5 to 10 members, unsubstituted or substituted one or more times by one (C ⁇ -C3) alkyl or by a (C ⁇ ⁇ C3) alkoxy;
- R4, R5, Rg, R7, Rg, Ro. each independently represent hydrogen, a halogen, a trifluoromethyl, and when R ⁇ represents a fluorine, R4, R5, Rg, R7, Rg and / or R9 can also represent a fluoromethyl; and provided that at least one of the substituents R4 or R7 is different from hydrogen;
- R o and Ru each independently represent hydrogen or a (C ⁇ ⁇ C5) alkyl or RJQ and RJ I together with the nitrogen atom to which they are linked constitute a heterocyclic radical chosen from pyrrolidin-1-yle, piperidin- 1-yl, morpholin-4-yl, piperazin-1-yl unsubstituted or substituted by a (C 1 -C 4 alkyl; as well as their salts and their solvates.
- (C 1 -C 3 ) alkyl (C! -C5) alkoxy, (C ⁇ -C5) alkylthio, is meant alkyl radicals or respectively C1-C3 or C1-C5 alkoxy or alkylthio radicals straight or branched.
- halogen is meant chlorine, fluorine, bromine or iodine, preferably chlorine.
- saturated or unsaturated 5 or 10-membered heterocyclic radical is meant a non-aromatic mono, di or tricyclic, condensed or bridged heterocyclic radical.
- These radicals include in particular the following radicals: pyrrolidin-1-yl, piperidin-1-yl, hexahydroazepin-1-yl, 2-azabicyclo [2.2.2] oct-5-en-2-yle, 2-azaadamant-2 -yle, 1,2,3, 6-tetrahydropyridin-1-yl, 2-azabicyclo [2.2.1] heptan-2-yl, 2-azabicyclo [2.2.2] octan-2-ylc.
- the salts of the compound of formula (I) include the addition salts of pharmaceutically acceptable acids such as the hydrochloride, the hydrobromide. sulfate, hydrogen sulfate, dihydrogen phosphate, methanesulfonate, methyl sulfate, maleate, oxalate, fumarate, 2-naphthalcncsuIfonate, glyconate. gluconate, citrate, isethionate, paratoluenesulfonate.
- pharmaceutically acceptable acids such as the hydrochloride, the hydrobromide. sulfate, hydrogen sulfate, dihydrogen phosphate, methanesulfonate, methyl sulfate, maleate, oxalate, fumarate, 2-naphthalcncsuIfonate, glyconate. gluconate, citrate, isethionate, paratoluenesulfonate.
- the subject of the present invention is the compounds of formula:
- R ⁇ p represents a fluorine, a methoxy or a methylthio, as well as their salts and their solvates.
- the present invention relates to a process for the preparation of the compounds of formula (I) above, their salts and their solvates; this process called Process 1 is characterized in that: a) a bromine ester of formula is treated:
- R4, R5, Rg, R7, Rg, R9 are as defined above and R represents a (C ⁇ -C4) alkyl, with a compound of formula: R'i A (III) in which R'i represents Ri as defined for (I) or a precursor of Ri and A represents a hydrogen or a cation; bl) in the ester thus obtained, R'i is optionally transformed into Ri; b2) the ester thus obtained in step a) or in step bl) is saponified, of formula: c) treating the acid thus obtained of formula:
- precursor of Ri is meant a group which can be transformed into Ri in a later step. This transformation can be carried out on the ester of formula (IV) obtained in step a) or on the compound of formula (I 1 ) obtained in step c).
- the brominated esters of formula (II) are described in European patent application EP-A-658 546. They are prepared by the action of N-bromosuccinimide in a solvent such as carbon tetrachloride, in the presence of benzoyl peroxide on a composed of formula:
- the hydrazines H2N-NR2R3 are known or prepared by known methods.
- the nitroso derivative (VIII) is obtained by reaction of a compound of formula: HNR2R3 (IX) in which R2 and R3 are as defined above for (I), with sodium nitrite in aqueous solution in the presence of an acid such as acetic acid.
- 1-aminopiperidine is commercial.
- 2-amino-2-azaadamantane is prepared from 2-azaadamantane, via the nitroso derivative.
- 2-azaadamantane is prepared according to J. Org. Chem., 1981, 4_6_, 4953.
- cation is meant an alkali or alkaline earth metal cation, or a quaternary ammonium group such as tetraethylammonium.
- an activated ester can be used, for example / 7-nitrophenyl ester, or the free acid suitably activated, for example, with N, N-dicyclohexylcarbodiimide, benzotriazol hexafluorophosphate-N-oxotris (dimethylamino) phosphonium (BOP) or silicon tetrachloride ( Commun.
- step c) the chloride of pyrazole-3-carboxylic acid, obtained by reaction of thionyl chloride with the acid of formula (V), can be reacted with a hydrazine H2N-NR2R3 (VI), in a solvent such as dichloromethane, under an ine ⁇ e atmosphere, at a temperature between 0 * C and room temperature, in the presence of a base such as triethylamine.
- a variant of the procedure of step c) consists in preparing the mixed anhydride of the acid of formula (V) by reaction of ethyl chloroformate with the acid of formula (V), in the presence of a base such as triethylamine, and reacting it with hydrazine, in a solvent such as dichloromethane, under an inert atmosphere, at room temperature, in the presence of a base such as triethylamine.
- an R'iA (III) reagent is used an alkali or alkaline alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, the acid of formula (V).
- R4, R5, Rg, R7, Rg, R9 and R are as defined above by an alkali or alkaline earth metal hydroxide; f) treating the acid thus obtained of formula:
- a metallic cyanide such as sodium cyanide or a quaternary ammonium cyanide, for example tetraethylammonium cyanide; in the latter case, the nucleophilic substitution reaction of step a) or of step h) is carried out in the presence of a phase transfer catalyst.
- fluorinating agent there may be mentioned a quaternary ammonium fluoride such as tetrabutylammonium fluoride; a metal fluoride, for example potassium fluoride used in the presence of a weak base such as potassium carbonate and a complexing agent such as Kryptofix®; a hydrofluoric acid complex, for example a (HF) n-
- a compound of formula (I) is prepared in which Ri represents a fluorine and R4, R5, Rg, R7, Rg and / or R9 represents a fluoromethyl using as starting material a compound of formula (II) in which R4, R5, Rg, R7, Rg and / or R9 represents bromomethyl.
- the fluorination carried out according to one of the methods described above makes it possible to transform R4, R5, Rg, R7, Rg and / or R9 into fluoromethyl.
- the starting compound (II) is prepared by action of N- 97/19063 y PO7FR96 / 01847
- a compound of formula (I) in which R ⁇ is a group -NRIQRH, it is possible to react in step a) an amine of formula: HNRIQRH (III) -
- a non-nucleophilic base such as a metal hydride, such as sodium hydride.
- the compound of formula (I) obtained by the process according to the invention is isolated, in the form of a free base or of salt or of solvate, according to conventional techniques.
- the compound of formula (I) can be isolated in the form of one of its salts, for example the hydrochloride or the oxalate; in this case, the free base can be prepared by neutralizing said salt with an inorganic or organic base, such as sodium or ammonium hydroxide, triethylamine or an alkali carbonate or bicarbonate such as sodium carbonate or bicarbonate or potassium, and transformed into another salt such as methanesulfonate, fumarate or 2- ⁇ aphthalenesulfonate.
- an inorganic or organic base such as sodium or ammonium hydroxide, triethylamine or an alkali carbonate or bicarbonate such as sodium carbonate or bicarbonate or potassium
- the salification is carried out by treatment with the chosen acid in an organic solvent.
- an organic solvent such as diethyl ether or in acetone
- the free base dissolved for example in an ether such as diethyl ether or in acetone
- the corresponding salt is obtained which is isolated according to conventional techniques.
- the compounds of formula (I) have a very good in vitro affinity for the central cannabinoid receptors, under the experimental conditions described by Devane et al., Molecular Pharmacology, 1988, 3.4, 605-613.
- the compounds of the present invention are potent and selective antagonists of the central cannabinoid receptors, having a Ki of between 1 and 100 nM. They are between 100 and 1000 times more active on central receptors than on peripheral receptors, are active orally and pass the blood-brain barrier.
- the compounds (I), as such or possibly in the form of salts pharmaceutically acceptable or solvates, can be used as active principles of medicaments intended to combat diseases of the central nervous system of mammals.
- the toxicity of the compounds (I) is compatible with their use as psychotropic drugs, in particular for the treatment of thymic disorders, anxiety disorders, mood disorders, vomiting, memory disorders, cognitive disorders, neuropathies , migraine, stress, psychosomatic illnesses, epilepsy, dyskinesias or
- the compounds (I) according to the invention can also be used as a medicament for the treatment of appetite disorders, in particular as an appetite suppressant, for the treatment of schizophrenia, delusional disorders, psychotic disorders in general, as well as disorders related to the use of psychotic substances.
- the compounds (I) according to the invention can be used as a medicament for anticancer chemotherapy.
- the compounds (I) according to the invention can be used as pharmacological tools in humans or in animals, for the detection and labeling of central cannabinoid receptors.
- the compounds of formula (I) in which Ri is a radioactive fluorine atom such as 1 ⁇ F can be used in studies of positron emission tomography in order to visualize in vivo the location and the density of the central cannabinoid receptors and to study the pharmacokinetics and biodistribution of central cannabinoid receptor agonists or antagonists.
- irreversible ligands comprising photoactivable groups or electrophilic groups such as for example an azido, an isothiocyanato, a haloacetamido, a Michael acceptor or an aldol ester.
- Irreversible ligands can be used to isolate, purify and characterize cannabinoid receptors, and identify their active site.
- the compounds according to the invention are generally administered in dosage units.
- Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
- the present invention relates to pharmaceutical compositions containing, as active principle, a compound of formula (I) or one of its pharmaceutically acceptable salts or one of their solvates.
- the compounds of formula (I) above and their pharmaceutically acceptable salts can be used in daily doses of 0.01 to 100 mg per kg of body weight of the mammal to be treated, preferably in daily doses of 0.1 to
- the dose may preferably vary from 0.5 to 4000 mg per day, more particularly from 2.5 to 1000 mg depending on the age of the subject to be treated or the type of treatment: prophylactic or curative.
- the active ingredient can be administered in unit administration form, in admixture with carriers conventional pharmaceuticals, animals and humans.
- suitable unit administration forms include oral forms such as tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, aerosols, implants, forms topical administration, subcutaneous, intramuscular, intravenous, intranasal or intraocular administration forms and forms of rectal administration.
- the active ingredient is generally formulated in dosage units containing from 0.5 to 1000 mg, advantageously from 1 to 500 mg, preferably from 2 to 200 mg of said active ingredient per dosage unit for daily administrations.
- a wetting agent such as sodium lauryl sulphate can be added to the active principle, micronized or not, and the whole is mixed with a pharmaceutical vehicle such as silica, starch. , lactose, magnesium stearate, talc or the like.
- the tablets can be coated with sucrose, various polymers or other suitable materials or else they can be treated so that they have a prolonged or delayed activity and that they continuously release a predetermined quantity of active principle.
- a preparation in capsules is obtained by mixing the active principle with a diluent such as a, glycol or a glycerol ester and by incorporating the mixture obtained in soft or hard capsules.
- a diluent such as a, glycol or a glycerol ester
- a preparation in the form of a syrup or elixir may contain the active principle together with a sweetener, preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and an appropriate color.
- a sweetener preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and an appropriate color.
- the water-dispersible powders or granules may contain the active principle in admixture with dispersing agents, wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners or taste.
- Suppositories are used for rectal administration which are prepared with binders that melt at rectal temperature, for example cocoa butter or polyethylene glycols.
- aqueous suspensions, isotonic saline solutions or sterile injectable solutions which contain pharmacologically compatible dispersing agents and / or solubilizing agents, for example propylene glycol or polyethylene glycol.
- a cosolvent can be used: an alcohol such as ethanol, a glycol such as polyethylene glycol or propylene glycol and a hydrophilic surfactant such as
- Tween® 80 To prepare an oily solution for injection by the intramuscular route, the active principle can be dissolved by a triglyceride or a glycerol ester.
- gels for local administration, gels, ointments or creams can be used.
- patches in multilaminate form or reservoirs in which the active principle is in alcoholic solution can be used.
- the active principle can also be formulated in the form of microcapsules or microspheres, optionally with one or more carriers or additives.
- the active principle can also be presented in the form of a complex with a cyclodextrin, for example ⁇ -, ⁇ - or ⁇ - cyclodextrin, 2-hydroxypropyl- ⁇ - cyclodextrin or methyl- ⁇ -cyclodextrin.
- implants can be used. These can be prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium.
- the melting or decomposition points of the products, F are measured in a capillary tube with a Tottoli device.
- Kryptofix® 4, 7, 13, 16, 21, 24-hexaoxa-1,10-diazabicyclo [8.8.8] -hexacosane
- TFA trifluoroacetic acid
- s singlet se: widened singlet d: doublet d. from d. : doublet of doublet t: triplet q: quadruple! m: multiplet or massive.
- PREPARATION 1 Methyl ester of 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4- bromomethylpyrazole-3-carboxylic acid.
- A) 5- (4-Chlorophenyl) -1- (2,4-dichlorophenyl) -4-methylpyrazole-3-carboxylic acid r-butyl ester A solution of 5 g of 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4-methylpyrazole-3-carboxylic acid in 35 ml of dioxane is introduced into a 250 ml autoclave, then cooled to - 10 * C. 2 ml of concentrated SO 2 SO 4 and 70 ml of 2-methylpropene cooled to -10 ° C. are then added, the autoclave is closed, the mixture is allowed to return to RT and then heated to 40 ° C.
- PREPARA ⁇ ON 8 and 0.68 g of sodium methylthiolate in 40 ml of THF Hydrolyzed by adding 50 ml of water, the THF is concentrated in vacuo, the remaining aqueous phase is extracted with DCM, the organic phase is washed with a saturated NaCl solution, dried over MgS ⁇ 4 and the solvent evaporated under vacuum. 2.51 g of the expected product are obtained.
- N- (piperidin-1 -yl) -5- (4-chloropheny 1) - 1 - (2,4-dichlorophenyl) -4- hydroxymethylpyrazole-3-carboxamide was placed 1.75 g of the compound of PREPARA ⁇ ON 2 in 30 ml of DCM are successively added 1.53 ml of triethylamine, 0.50 ml of 1-aminopiperidine and then, at 0 ° C, 2.33 g of BOP. The mixture is left stirring at 0 ° C. for 10 minutes and then at RT for 3.5 hours.
- reaction medium is poured into 100 ml of ice water, extracted with DCM, washed with water, with a saturated NaCl solution, then dried over MgS ⁇ 4- The residue obtained is chromatographed on fine silica eluting with AcOEt / toluene
- This compound can also be prepared by following the procedure described below.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/068,869 US6028084A (en) | 1995-11-23 | 1996-11-21 | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
JP9519454A JP2000500479A (ja) | 1995-11-23 | 1996-11-21 | ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物 |
AU76985/96A AU7698596A (en) | 1995-11-23 | 1996-11-21 | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
DK96939962T DK0876350T3 (da) | 1995-11-23 | 1996-11-21 | Pyrazolderivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne |
AT96939962T ATE203015T1 (de) | 1995-11-23 | 1996-11-21 | Pyrazol-derivate, verfahren für ihre herstellung und sie enthaltende zusammensetzungen |
EP96939962A EP0876350B1 (fr) | 1995-11-23 | 1996-11-21 | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant |
DE69613860T DE69613860T2 (de) | 1995-11-23 | 1996-11-21 | Pyrazol-derivate, verfahren für ihre herstellung und sie enthaltende zusammensetzungen |
BR9611618A BR9611618A (pt) | 1995-11-23 | 1996-11-21 | Composto processo para sua preparação composição farmacêutica e utilização de um compostos |
CA002238430A CA2238430C (fr) | 1995-11-23 | 1996-11-21 | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant |
NO19982330A NO310508B1 (no) | 1995-11-23 | 1998-05-22 | Pyrazol-derivater, anvendelse derav, fremgangsmåter for fremstilling derav, og farmasöytiske preparater inneholdendenevnte derivater |
GR20010401691T GR3036830T3 (en) | 1995-11-23 | 2001-10-08 | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR95/13956 | 1995-11-23 | ||
FR9513956A FR2741621B1 (fr) | 1995-11-23 | 1995-11-23 | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997019063A1 true WO1997019063A1 (fr) | 1997-05-29 |
Family
ID=9484869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/001847 WO1997019063A1 (fr) | 1995-11-23 | 1996-11-21 | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant |
Country Status (16)
Country | Link |
---|---|
US (1) | US6028084A (fr) |
EP (1) | EP0876350B1 (fr) |
JP (1) | JP2000500479A (fr) |
AT (1) | ATE203015T1 (fr) |
AU (1) | AU7698596A (fr) |
BR (1) | BR9611618A (fr) |
CA (1) | CA2238430C (fr) |
DE (1) | DE69613860T2 (fr) |
DK (1) | DK0876350T3 (fr) |
ES (1) | ES2161382T3 (fr) |
FR (1) | FR2741621B1 (fr) |
GR (1) | GR3036830T3 (fr) |
MX (1) | MX9803891A (fr) |
NO (1) | NO310508B1 (fr) |
PT (1) | PT876350E (fr) |
WO (1) | WO1997019063A1 (fr) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0979228A1 (fr) * | 1997-03-18 | 2000-02-16 | Smithkline Beecham Corporation | Nouveaux agonistes de recepteurs de cannabinoides |
FR2800375A1 (fr) * | 1999-11-03 | 2001-05-04 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
US6630507B1 (en) | 1998-04-21 | 2003-10-07 | The United States Of America As Represented By The Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
WO2004035548A1 (fr) * | 2002-10-16 | 2004-04-29 | Astrazeneca Ab | Nouveaux composes |
WO2004060870A1 (fr) * | 2003-01-02 | 2004-07-22 | F. Hoffmann-La Roche Ag | Nouveaux agonistes inverses du recepteur cb 1 |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
FR2856684A1 (fr) * | 2003-06-26 | 2004-12-31 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
US6900227B2 (en) | 2002-07-29 | 2005-05-31 | Hoffmann-La Roche Inc. | Benzodioxole derivatives |
WO2005108393A1 (fr) | 2004-05-10 | 2005-11-17 | F. Hoffmann-La Roche Ag | Amides pyrroles ou imidazoles destines au traitement de l'obesite |
EP1623741A2 (fr) | 2004-07-22 | 2006-02-08 | Cadila Healthcare Ltd. | LIGANDS DU RECEPTEUR CANNABINOIDE pour moduler LA POUSSE DES CHEVEUX |
FR2874012A1 (fr) * | 2004-08-09 | 2006-02-10 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
US7037944B2 (en) | 2000-10-04 | 2006-05-02 | Aventis Pharma S.A. | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
WO2006050842A1 (fr) | 2004-11-09 | 2006-05-18 | F. Hoffmann-La Roche Ag | Derives dibenzosuberone |
WO2006067443A1 (fr) * | 2004-12-23 | 2006-06-29 | Astrazeneca Ab | Agents thérapeutiques |
US7135488B2 (en) | 2003-01-02 | 2006-11-14 | Hoffmann-La Roche Inc. | Pyrrolyl-thiazole derivatives |
US7144890B2 (en) | 2004-01-28 | 2006-12-05 | Hoffman-La Roche Inc. | Spiro-pentacyclic compounds |
US7229999B2 (en) | 2005-04-06 | 2007-06-12 | Hoffmann-La Roche Inc. | Pyridine-3-carboxamide derivatives as CB1 inverse agonists |
BG65193B1 (bg) * | 1999-02-01 | 2007-06-29 | Sanofi-Synthelabo | Производно на пиразолкарбоксилна киселина, неговото използване и фармацевтични състави, които го съдържат |
US7297707B2 (en) | 2003-06-20 | 2007-11-20 | Hoffmann-La Roche Inc. | Benzothiazolyl derivatives |
US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
US7371751B2 (en) | 2003-12-08 | 2008-05-13 | Hoffmann-La Roche Inc. | Thiazole derivatives |
US7384945B2 (en) | 2004-10-27 | 2008-06-10 | Hoffmann-La Roche Inc. | Indole or benzimidazole derivatives as CB1 inverse agonists |
WO2008075012A1 (fr) | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Modulateurs de récepteur cb1 |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
EP2368881A1 (fr) * | 2005-01-10 | 2011-09-28 | University of Connecticut | Nouveaux analogues d'hétéropyrazole agissant en tant que récepteurs de cannabinoïde |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
US8853205B2 (en) | 2005-01-10 | 2014-10-07 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
US10053444B2 (en) | 2009-02-19 | 2018-08-21 | University Of Connecticut | Cannabinergic nitrate esters and related analogs |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69910373T2 (de) * | 1998-05-04 | 2004-04-01 | The University Of Connecticut, Farmington | Analgetische und immunomodulierende cannabinoiden |
US7589220B2 (en) * | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
US7897598B2 (en) * | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
US7276613B1 (en) | 1998-11-24 | 2007-10-02 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
US7161016B1 (en) | 1998-11-24 | 2007-01-09 | University Of Connecticut | Cannabimimetic lipid amides as useful medications |
US6943266B1 (en) * | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US7741365B2 (en) * | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
US7119108B1 (en) * | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
MXPA02005103A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Ligandos selectivos del receptor de canabinoide (cb2) perifericos. |
US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
CN1438900A (zh) * | 2000-05-23 | 2003-08-27 | 加利福尼亚大学董事会 | 一种治疗咳嗽的新方法 |
EP1361876A4 (fr) * | 2001-01-26 | 2004-03-31 | Univ Connecticut | Nouveaux ligands cannabimimetiques |
ATE478670T1 (de) | 2001-01-29 | 2010-09-15 | Univ Connecticut | Rezeptor-selektive cannabimimetische aminoalkylindole |
US7057076B2 (en) * | 2001-07-13 | 2006-06-06 | University Of Connecticut | Bicyclic and tricyclic cannabinoids |
WO2003007887A2 (fr) * | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides |
US7666867B2 (en) * | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
WO2003063781A2 (fr) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Imidazoles substitues en tant que modulateurs du recepteur cannabinoide |
NZ534757A (en) * | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
JP2005528366A (ja) * | 2002-03-26 | 2005-09-22 | メルク エンド カムパニー インコーポレーテッド | カンナビノイド受容体モジュレータとしてのスピロ環式アミド |
US7271266B2 (en) * | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
CA2480856A1 (fr) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Arylamides substituee |
US7667053B2 (en) * | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
ATE375349T1 (de) * | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
CA2496097A1 (fr) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Ceto-cannabinoides possedant des indications therapeutiques |
US7319110B2 (en) * | 2002-09-19 | 2008-01-15 | Solvay Pharmaceuticals B.V. | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity |
US7765162B2 (en) * | 2002-10-07 | 2010-07-27 | Mastercard International Incorporated | Method and system for conducting off-line and on-line pre-authorized payment transactions |
MXPA05004115A (es) * | 2002-10-18 | 2005-06-22 | Pfizer Prod Inc | Ligandos del receptor cannabionoide y usos de los mismos. |
ITMI20022228A1 (it) * | 2002-10-21 | 2004-04-22 | Dinamite Dipharma S P A | Sali di clopidogrel con acidi alchil-solforici. |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
EP1641493A4 (fr) * | 2003-06-30 | 2007-10-31 | Merck & Co Inc | Modulateurs radiomarques du recepteur de cannabinoide-1 |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
CA2551037A1 (fr) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
TW200522944A (en) | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
AU2005230864A1 (en) | 2004-03-29 | 2005-10-20 | Merck Sharp & Dohme Corp. | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
ITMI20041033A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
KR20070041717A (ko) | 2004-07-12 | 2007-04-19 | 카딜라 핼쓰캐어 리미티드 | 카나비노이드 수용체 조절자인 트리시클릭 피라졸 유도체들 |
AU2005271527B2 (en) | 2004-08-06 | 2009-08-27 | Merck Sharp & Dohme Corp. | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
EP1784390A2 (fr) * | 2004-08-13 | 2007-05-16 | Amgen Inc. | Heterocycles benzo-condenses substitues |
JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
JP4926069B2 (ja) | 2004-11-01 | 2012-05-09 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 肥満ならびに肥満関連疾患および障害の治療方法 |
JP2008525401A (ja) * | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療薬 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US20060278280A1 (en) * | 2005-05-23 | 2006-12-14 | Tzai-Jen Yang | Check valve |
JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−1受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
US7923465B2 (en) * | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
KR100970055B1 (ko) * | 2005-06-22 | 2010-07-16 | 에프. 호프만-라 로슈 아게 | 6-(플루오로-벤조[1,3]디옥솔일)-모폴린-4-일-메탄온 및cb1 리간드로서 그의 용도 |
CA2518579A1 (fr) * | 2005-08-05 | 2007-02-05 | University Technologies International Inc. | Methode anorexigene |
WO2007018248A1 (fr) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Composé de pyridone |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
DE602006017712D1 (de) | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | Phenylpyridonderivat |
JPWO2007029847A1 (ja) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
WO2007041052A2 (fr) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4 |
EP1944301A4 (fr) | 2005-10-27 | 2012-01-04 | Msd Kk | Nouveau derive de benzoxathiine |
ES2381205T3 (es) | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
EP1801098A1 (fr) | 2005-12-16 | 2007-06-27 | Merck Sante | Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1 |
ATE538650T1 (de) * | 2006-03-10 | 2012-01-15 | Jenrin Discovery | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht |
EP2698157B1 (fr) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
AU2007301126A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
US20080108643A1 (en) * | 2006-11-03 | 2008-05-08 | Forest Laboratories Holdings Limited | Method for treating autism |
EP1935420A1 (fr) | 2006-12-21 | 2008-06-25 | Merck Sante | Dérivés du 2-adamantyl-butyramide en tant qu'inhibiteurs selectifs de la 11beta-HSD1 |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
PE20090142A1 (es) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2688161C (fr) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
US8293786B2 (en) * | 2007-07-30 | 2012-10-23 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
BRPI0722276A2 (pt) * | 2007-11-14 | 2014-04-22 | Amylin Pharmaceuticals Inc | Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
WO2009074782A1 (fr) * | 2007-12-10 | 2009-06-18 | 7Tm Pharma A/S | Modulateurs du récepteur de cannabinoïdes |
JP5704925B2 (ja) * | 2008-02-08 | 2015-04-22 | ウェルズ ファーゴ バンク ナショナル アソシエイション | オリゴマー−カンナビノイドコンジュゲート |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
EP2264026A4 (fr) | 2008-03-06 | 2012-03-28 | Msd Kk | Dérivé d'alkylaminopyridine |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
EP2110374A1 (fr) | 2008-04-18 | 2009-10-21 | Merck Sante | Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR |
CA2726917C (fr) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
EP2149370A1 (fr) | 2008-07-31 | 2010-02-03 | Neuroscienze Pharmaness S.C. A R.L. | Composés diazabicycliques et microémulsions comprenant les mêmes |
IT1390848B1 (it) * | 2008-07-31 | 2011-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
JP5635991B2 (ja) | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | イソニコチンアミドオレキシン受容体アンタゴニスト |
JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
WO2010056717A1 (fr) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Amines bicycliques substituées pour le traitement du diabète |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
EP2379547A1 (fr) | 2008-12-16 | 2011-10-26 | Schering Corporation | Dérivés de pyridopyrimidine et leurs procédés d'utilisation |
WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
IT1395724B1 (it) * | 2009-02-25 | 2012-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
IT1394400B1 (it) | 2009-02-25 | 2012-06-15 | Neuroscienze Pharmaness S C Ar L | Composizioni farmaceutiche |
IT1394860B1 (it) | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
DE102009035649A1 (de) * | 2009-07-29 | 2011-02-03 | Siemens Aktiengesellschaft | Arzneistoff und Verfahren zur Erprobung eines Arzneistoffes |
CA2779088A1 (fr) | 2009-11-16 | 2011-05-19 | Mellitech | Derives de [1,5]-diazocine |
IT1396951B1 (it) * | 2009-12-18 | 2012-12-20 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
CN103664873B (zh) | 2009-12-30 | 2016-06-15 | 深圳信立泰药业股份有限公司 | 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物 |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011137024A1 (fr) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase |
EP2568812B1 (fr) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs inédits de la prolylcarboxypeptidase |
US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP3243385B1 (fr) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
AU2012316331B2 (en) | 2011-09-30 | 2016-02-25 | National Health Research Institutes | Pyrazole compounds |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP2958562A4 (fr) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | Composés bicycliques antidiabétiques |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
EP2970384A1 (fr) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
CA2905435A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
EP2789619A1 (fr) | 2013-04-12 | 2014-10-15 | Kemotech S.r.l. | Composés pharmaceutiques ayant une activité inhibitrice de l'angiogenèse |
CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
WO2015188073A1 (fr) | 2014-06-06 | 2015-12-10 | Research Triangle Institute | Agonistes du récepteur de l'apeline (apj) et leurs utilisations |
MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
US10100059B2 (en) | 2015-12-09 | 2018-10-16 | Research Triangle Institute | Apelin receptor (APJ) agonists and uses thereof |
AR109950A1 (es) | 2016-10-14 | 2019-02-06 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
EP3551176A4 (fr) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
TW202033516A (zh) | 2018-11-20 | 2020-09-16 | 義大利商Tes製藥(股份)責任有限公司 | α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑 |
WO2020167706A1 (fr) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine |
EP4010314B1 (fr) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle |
CA3125847A1 (fr) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Procede de fabrication de composes biologiquement actifs et d'intermediaires connexes |
EP4200295A1 (fr) | 2020-08-18 | 2023-06-28 | Merck Sharp & Dohme LLC | Agonistes du récepteur de l'orexine de type bicycloheptane pyrrolidine |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3449350A (en) * | 1968-06-24 | 1969-06-10 | Ciba Geigy Corp | Certain pyrazole-3-carboxylic acid hydrazide derivatives |
EP0477049A1 (fr) * | 1990-08-20 | 1992-03-25 | Sanofi | Dérivés d'amido-3 pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0576357A1 (fr) * | 1992-06-23 | 1993-12-29 | Sanofi | Dérivés du pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0647629A1 (fr) * | 1993-10-12 | 1995-04-12 | Sanofi | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant |
EP0656354A1 (fr) * | 1993-12-02 | 1995-06-07 | Sanofi | N-pipéridino-3-pyrazolecarboxamide substitué |
EP0658546A1 (fr) * | 1993-12-17 | 1995-06-21 | Sanofi | Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides |
-
1995
- 1995-11-23 FR FR9513956A patent/FR2741621B1/fr not_active Expired - Fee Related
-
1996
- 1996-11-21 ES ES96939962T patent/ES2161382T3/es not_active Expired - Lifetime
- 1996-11-21 DK DK96939962T patent/DK0876350T3/da active
- 1996-11-21 CA CA002238430A patent/CA2238430C/fr not_active Expired - Fee Related
- 1996-11-21 AT AT96939962T patent/ATE203015T1/de not_active IP Right Cessation
- 1996-11-21 DE DE69613860T patent/DE69613860T2/de not_active Expired - Lifetime
- 1996-11-21 EP EP96939962A patent/EP0876350B1/fr not_active Expired - Lifetime
- 1996-11-21 WO PCT/FR1996/001847 patent/WO1997019063A1/fr active IP Right Grant
- 1996-11-21 AU AU76985/96A patent/AU7698596A/en not_active Abandoned
- 1996-11-21 JP JP9519454A patent/JP2000500479A/ja active Pending
- 1996-11-21 PT PT96939962T patent/PT876350E/pt unknown
- 1996-11-21 BR BR9611618A patent/BR9611618A/pt not_active Application Discontinuation
- 1996-11-21 US US09/068,869 patent/US6028084A/en not_active Expired - Lifetime
-
1998
- 1998-05-15 MX MX9803891A patent/MX9803891A/es unknown
- 1998-05-22 NO NO19982330A patent/NO310508B1/no unknown
-
2001
- 2001-10-08 GR GR20010401691T patent/GR3036830T3/el not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3449350A (en) * | 1968-06-24 | 1969-06-10 | Ciba Geigy Corp | Certain pyrazole-3-carboxylic acid hydrazide derivatives |
EP0477049A1 (fr) * | 1990-08-20 | 1992-03-25 | Sanofi | Dérivés d'amido-3 pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0576357A1 (fr) * | 1992-06-23 | 1993-12-29 | Sanofi | Dérivés du pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0647629A1 (fr) * | 1993-10-12 | 1995-04-12 | Sanofi | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant |
EP0656354A1 (fr) * | 1993-12-02 | 1995-06-07 | Sanofi | N-pipéridino-3-pyrazolecarboxamide substitué |
EP0658546A1 (fr) * | 1993-12-17 | 1995-06-21 | Sanofi | Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0979228A4 (fr) * | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | Nouveaux agonistes de recepteurs de cannabinoides |
EP0979228A1 (fr) * | 1997-03-18 | 2000-02-16 | Smithkline Beecham Corporation | Nouveaux agonistes de recepteurs de cannabinoides |
US6630507B1 (en) | 1998-04-21 | 2003-10-07 | The United States Of America As Represented By The Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
BG65193B1 (bg) * | 1999-02-01 | 2007-06-29 | Sanofi-Synthelabo | Производно на пиразолкарбоксилна киселина, неговото използване и фармацевтични състави, които го съдържат |
WO2001032663A3 (fr) * | 1999-11-03 | 2001-09-27 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
US6906080B1 (en) | 1999-11-03 | 2005-06-14 | Sanofi-Aventis | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
WO2001032663A2 (fr) * | 1999-11-03 | 2001-05-10 | Sanofi-Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
FR2800375A1 (fr) * | 1999-11-03 | 2001-05-04 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
US7384960B2 (en) | 1999-11-03 | 2008-06-10 | Sanofi-Aventis | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
US7148258B2 (en) | 2000-10-04 | 2006-12-12 | Aventis Pharma S.A. | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
US7037944B2 (en) | 2000-10-04 | 2006-05-02 | Aventis Pharma S.A. | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
US7576088B2 (en) | 2002-07-29 | 2009-08-18 | Hoffman-La Roche Inc. | Benzodioxole derivatives |
US6900227B2 (en) | 2002-07-29 | 2005-05-31 | Hoffmann-La Roche Inc. | Benzodioxole derivatives |
WO2004035548A1 (fr) * | 2002-10-16 | 2004-04-29 | Astrazeneca Ab | Nouveaux composes |
US7407968B2 (en) | 2002-10-16 | 2008-08-05 | Astrazeneca Ab | Compounds |
US7579369B2 (en) | 2003-01-02 | 2009-08-25 | Hoffmann-La Roche Inc. | CB 1 receptor inverse agonists |
US7294644B2 (en) | 2003-01-02 | 2007-11-13 | Hoffmann-La Roche Inc. | CB 1 receptor inverse agonists |
US7135488B2 (en) | 2003-01-02 | 2006-11-14 | Hoffmann-La Roche Inc. | Pyrrolyl-thiazole derivatives |
WO2004060870A1 (fr) * | 2003-01-02 | 2004-07-22 | F. Hoffmann-La Roche Ag | Nouveaux agonistes inverses du recepteur cb 1 |
KR100704097B1 (ko) * | 2003-01-02 | 2007-04-06 | 에프. 호프만-라 로슈 아게 | 신규 cb 1 수용체 역작용제 |
US7297707B2 (en) | 2003-06-20 | 2007-11-20 | Hoffmann-La Roche Inc. | Benzothiazolyl derivatives |
WO2005000820A3 (fr) * | 2003-06-25 | 2005-03-17 | Sanofi Aventis | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1 |
WO2005000820A2 (fr) * | 2003-06-25 | 2005-01-06 | Sanofi-Aventis | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1 |
FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
WO2005000817A2 (fr) * | 2003-06-26 | 2005-01-06 | Sanofi-Aventis | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
FR2856684A1 (fr) * | 2003-06-26 | 2004-12-31 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
WO2005000817A3 (fr) * | 2003-06-26 | 2005-03-17 | Sanofi Aventis | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
US7345059B2 (en) | 2003-06-26 | 2008-03-18 | Sanofi-Aventis | Diphenylpyridine derivatives, preparation and therapeutic application thereof |
US7371751B2 (en) | 2003-12-08 | 2008-05-13 | Hoffmann-La Roche Inc. | Thiazole derivatives |
US7144890B2 (en) | 2004-01-28 | 2006-12-05 | Hoffman-La Roche Inc. | Spiro-pentacyclic compounds |
WO2005108393A1 (fr) | 2004-05-10 | 2005-11-17 | F. Hoffmann-La Roche Ag | Amides pyrroles ou imidazoles destines au traitement de l'obesite |
US7563910B2 (en) | 2004-05-10 | 2009-07-21 | Hoffmann-La Roche Inc. | Heterocyclic cannabinoid receptor antagonists |
EP1623741A2 (fr) | 2004-07-22 | 2006-02-08 | Cadila Healthcare Ltd. | LIGANDS DU RECEPTEUR CANNABINOIDE pour moduler LA POUSSE DES CHEVEUX |
WO2006024777A1 (fr) * | 2004-08-09 | 2006-03-09 | Sanofi-Aventis | Derives de pyrrole, leur preparation et leur utilisation en therapeutique |
EA012726B1 (ru) * | 2004-08-09 | 2009-12-30 | Санофи-Авентис | Производные пиррола, их получение и их применение в терапии |
US7879902B2 (en) | 2004-08-09 | 2011-02-01 | Sanofi-Aventis | Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof |
US7381727B2 (en) | 2004-08-09 | 2008-06-03 | Sanofi-Aventis | Pyrrole derivatives, their preparation and their therapeutic use |
FR2874012A1 (fr) * | 2004-08-09 | 2006-02-10 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
US7384945B2 (en) | 2004-10-27 | 2008-06-10 | Hoffmann-La Roche Inc. | Indole or benzimidazole derivatives as CB1 inverse agonists |
US7786128B2 (en) | 2004-10-27 | 2010-08-31 | Hoffmann-La Roche Inc. | Indole or benzimidazole derivatives as CB1 inverse agonists |
US7220743B2 (en) | 2004-11-09 | 2007-05-22 | Hoffmann-La Roche Inc. | Heterocyclic CB1 receptor antagonists |
WO2006050842A1 (fr) | 2004-11-09 | 2006-05-18 | F. Hoffmann-La Roche Ag | Derives dibenzosuberone |
WO2006067443A1 (fr) * | 2004-12-23 | 2006-06-29 | Astrazeneca Ab | Agents thérapeutiques |
EP2368881A1 (fr) * | 2005-01-10 | 2011-09-28 | University of Connecticut | Nouveaux analogues d'hétéropyrazole agissant en tant que récepteurs de cannabinoïde |
US8853205B2 (en) | 2005-01-10 | 2014-10-07 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
US7229999B2 (en) | 2005-04-06 | 2007-06-12 | Hoffmann-La Roche Inc. | Pyridine-3-carboxamide derivatives as CB1 inverse agonists |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
WO2008075012A1 (fr) | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Modulateurs de récepteur cb1 |
US10053444B2 (en) | 2009-02-19 | 2018-08-21 | University Of Connecticut | Cannabinergic nitrate esters and related analogs |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
Also Published As
Publication number | Publication date |
---|---|
ATE203015T1 (de) | 2001-07-15 |
NO310508B1 (no) | 2001-07-16 |
PT876350E (pt) | 2001-12-28 |
CA2238430A1 (fr) | 1997-05-29 |
GR3036830T3 (en) | 2002-01-31 |
DE69613860T2 (de) | 2002-04-04 |
EP0876350B1 (fr) | 2001-07-11 |
MX9803891A (es) | 1998-09-30 |
FR2741621B1 (fr) | 1998-02-13 |
US6028084A (en) | 2000-02-22 |
CA2238430C (fr) | 2006-05-09 |
DK0876350T3 (da) | 2001-11-05 |
JP2000500479A (ja) | 2000-01-18 |
DE69613860D1 (de) | 2001-08-16 |
ES2161382T3 (es) | 2001-12-01 |
NO982330L (no) | 1998-05-22 |
BR9611618A (pt) | 1999-03-30 |
FR2741621A1 (fr) | 1997-05-30 |
AU7698596A (en) | 1997-06-11 |
NO982330D0 (no) | 1998-05-22 |
EP0876350A1 (fr) | 1998-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0876350B1 (fr) | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
EP0658546B1 (fr) | Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides | |
EP0656354B1 (fr) | N-pipéridino-3-pyrazolecarboxamide substitué | |
EP1230244B1 (fr) | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant | |
EP1150961B1 (fr) | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant | |
EP0868420B1 (fr) | Derives de 3-pyrazolecarboxamide avec une affinite pour le recepteur des cannabinoides | |
EP0576357B1 (fr) | Dérivés du pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
EP1230222B1 (fr) | Derives tricycliques d'acides 1-benzylpyrazole-3-carboxylique comme antagonistes des recepteurs de cannabinoides | |
FR2732967A1 (fr) | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant | |
FR2831883A1 (fr) | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant | |
JPH09501650A (ja) | 治療薬としてのイミダゾール誘導体 | |
FR2711140A1 (fr) | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. | |
FR2789078A1 (fr) | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant | |
FR2713224A1 (fr) | N-pipéridino-3-pyrazolecarboxamide substitué. | |
JPH069624A (ja) | トリアゾール誘導体 | |
CZ280202B6 (cs) | Nové deriváty kyseliny thiofen-2-karboxylové a způsob jejich výroby | |
FR3008698A1 (fr) | Procede pour la production d'un actif pharmaceutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1997 519454 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/1998/003891 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09068869 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2238430 Country of ref document: CA Ref document number: 2238430 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996939962 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996939962 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996939962 Country of ref document: EP |